Clinical Trials Study
Copyright ©The Author(s) 2020.
World J Clin Cases. Nov 26, 2020; 8(22): 5564-5575
Published online Nov 26, 2020. doi: 10.12998/wjcc.v8.i22.5564
Figure 1
Figure 1 A 56-year-old woman who underwent gemcitabine plus concurrent for pancreatic head cancer. A: Enhanced computed tomography image showing a pancreatic head tumor measuring 3.9 cm × 4.8 cm; B: Irreversible electroporation ablation was performed; C: The tumor has shrunk to 3.5 cm × 2.1 cm 6 mo post-irreversible electroporation.
Figure 2
Figure 2 Kaplan-Meier survival curves. A: Graph showing overall survival from the time of diagnosis; B: Graph showing overall survival progression–free survival. GEM: Gemcitabine; IRE: Irreversible electroporation.